Pilot Study of a Remotely Delivered Personalized Physical Activity Program for Adults With Treatment-Resistant Depression
Led by Unity Health Toronto · Updated on 2025-04-30
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying adults with treatment-resistant depression TRD, a condition where people do not respond to at least two antidepressant medications. This pilot randomized controlled trial aims to evaluate the feasibility and acceptability of a remotely delivered, personalized physical activity PA program called MoveU.HappyU, combined with usual treatment, compared to usual treatment alone. The study also monitors the programs impact on depression, anxiety, and quality of life using wearable devices and questionnaires.
Participants will be randomly assigned in a 21 ratio to either receive a 4-week individualized PA program plus their usual treatment or just their usual treatment. The PA program involves weekly virtual sessions with a trainer including 30 minutes of behavioral coaching and 30 minutes of tailored aerobic or resistance exercise. Participants are also encouraged to do additional exercise independently for 120 minutes weekly at moderate intensity. Those not in the PA group will receive educational material about physical activity recommendations.
During the study, participants will complete mental health assessments, wear a device that collects physiological data, and use self-report questionnaires. After the 4-week intervention, there is a 6-week follow-up period to observe lasting effects. The main outcomes measured include the programs feasibility and acceptability over 13 weeks, along with changes in depression and anxiety symptoms and well-being. The total participation time spans approximately 10 weeks from intervention start through follow-up.
CONDITIONS
Brief Title
Physical Activity Program for TRD
Research Team
V
Venkat Bhat
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with major depressive disorder without psychotic symptoms, currently experiencing a major depressive episode confirmed by a structured interview
Montgomery-�c5sberg Depression Rating Scale score of 7 or higher at screening
Have failed at least two adequate antidepressant treatments during the current episode
Receiving treatment consistent with Canadian guidelines with no changes in the past 28 days
You will not qualify if you...
Current symptoms of mania, hypomania, mixed episodes, or psychosis
Diagnosis of alcohol or substance use disorder within the past 3 months
Pregnant females
Acute cardiovascular risk or event in the past 12 months
Medical contraindications to exercise
Balance, gait, or locomotion difficulties preventing participation
Other conditions affecting study completion as judged by investigators
Exercise-induced asthma
Taking medications interfering with heart rate response such as beta blockers
Do not own a smartphone
Lack reliable Internet access
Received intravenous ketamine treatment in the last 2 months
Non-English speaking individuals due to communication requirements
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or virtual) for eligibility assessment
Treatment
Duration - 4 weeks
Participants in the PA group will engage in a 4-week remotely delivered, one-on-one individualized physical activity program alongside treatment as usual (TAU). This includes weekly virtual sessions with a trainer and independent physical activity. Participants in the TAU group will receive PA guidelines and encouragement to exercise.
Weekly virtual visits for 4 weeks for the PA group; TAU group receives handout and encouragement
Follow-up
Duration - 6 weeks
Participants enter a 6-week observational follow-up period to monitor depressive and anxiety symptoms, quality of life, and physiological data collected via a wearable device.
Assessments and wearable device data collection during follow-up period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Trial of 40 Hz Light Neurostimulation Therapy to Treat Major Depressive Disorder
Evaluating 5-hydroxytryptophan and Creatine Supplements to Enhance Antidepressant Treatment in Adults with Major Depressive Disorder Using Brain Imaging and Serotonin Measures
Comparing Two Psychotherapy Treatments for Adults with Persistent, Treatment-Resistant Depression
Cognitive Behavioral Analysis System of Psychotherapy CBASP vs. Behavioral Activation BA in Inpatient and Outpatient Care
Randomized Study Evaluating a Single Oral Dose of CYB003 to Understand Brain and Symptom Changes in Adults With Major Depressive Disorder and Anxiety
Phase 2 Study on the Safety and Effectiveness of Zelquistinel Compared to Placebo for Treating Major Depressive Disorder in Adults Aged 18 to 64
Evaluating Oral DT120 Compared to Placebo in Adults With Major Depressive Disorder
A 12-Week Double-Blind Study Followed by a 40-Week Open-Label Extension
Psilocybin and Brain Activity Changes in Adults With Depression A Randomized Neuroimaging Study
Evaluating Vortioxetine for Major Depressive Disorder in Japanese Teens Aged 12 to 17 Using Daily Oral Tablets Compared to Placebo
Phase 2 Study of Oral Icalcaprant for Treating Major Depressive Disorder in Adults Aged 18 to 65
Evaluating Valbenazine for Adults With Tardive Dyskinesia Experiencing Symptoms During or After VMAT2 Inhibitor Treatment
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Improving adherence to physical activity in treatment-resistant depression: Protocol for a pilot randomized controlled trial of a remotely delivered program.
Vanessa K Tassone, Danika A Quesnel, Karisa Parkington...